Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: psoriasis

What Clinical Factors Affect Length of Transition to Psoriatic Arthritis in Patients with Psoriasis?

Shashank Cheemalavagu, MD, Yuxuan Jin, MS, & M. Elaine Husni, MD, MPH  |  December 9, 2024

Objective We aimed to identify clinical and demographic features associated with the interval between the appearance of psoriasis and the onset of psoriatic arthritis (PsA). Methods We identified patients with psoriasis and PsA diagnoses from our tertiary care psoriatic disease biorepository: a longitudinal, real-world database including clinical information and patient-reported outcomes. We used a multivariable,…

Filed under:American College of RheumatologyConditionsPsoriatic ArthritisResearch ReviewsResearch Rheum Tagged with:PsA Resource CenterPsoriasisPsoriatic Arthritis

Many Medications: Understanding the Biologic Management of Psoriasis

Jason Liebowitz, MD, FACR  |  June 15, 2023

ORLANDO, FLORIDA — Given the intersection between rheumatology and dermatology for many patients with autoimmune diseases, it’s helpful to hear from specialists in both fields regarding disease management strategies.

Filed under:Biologics/DMARDsConditionsDrug UpdatesMeeting ReportsOther ACR meetings Tagged with:ACR Education ExchangeACR Education Exchange 2023BiologicsPsoriasis

Risk of IBD in Patients with Psoriasis, PsA & Ankylosing Spondylitis Starting IL-17 Inhibitors

Arthritis & Rheumatology  |  February 2, 2022

In February A&R, Penso et al. reported on the results of their study, which explored whether patients with psoriasis, PsA and AS have a higher risk of developing IBD when treated with an IL-17 inhibitor compared with apremilast, a phosphodiesterase 4 (PDE4) inhibitor, or etanercept, a TNF inhibitor.

Filed under:ConditionsResearch Rheum Tagged with:Ankylosing SpondylitisArthritis & RheumatologyIBDIL-17IL-17 Inhibitorsinflammatory bowel disease (IBD)PsAPsoriatic ArthritisResearch

Study Finds Mirikizumab Superior to Secukinumab for Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  August 7, 2020

In a comparison study, subcutaneous mirikizumab proved superior to subcutaneous in achieving skin clearance in patients with plaque psoriasis…

Filed under:Biologics/DMARDsDrug Updates Tagged with:mirikizumabplaque psoriasissecukinumab

Study Finds Increased Risk of Cancer in Psoriasis Patients

Lara C. Pullen, PhD  |  August 5, 2020

Recent research reinforces the finding that psoriasis patients have a slightly increased risk of cancer, specifically keratinocyte cancer and lymphomas. However, the study found no association between cancer and the use of biologic treatments in this patient population…

Filed under:Conditions Tagged with:Cancercancer riskPsoriasis

Study Compares Ixekizumab with Ustekinumab for the Treatment of Nail Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  August 4, 2020

In a head-to-head study, ixekizumab was a more effective treatment for nail psoriasis than ustekinumab and resulted in greater skin clearance for patients with plaque psoriasis…

Filed under:Drug Updates Tagged with:ixekizumabnail psoriasisPsoriasisustekinumab

Ixekizumab May Improve Pain & Sexual Health in Patients with Genital Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  July 14, 2020

Research has shown ixekizumab improves pain and the sexual health of patients with genital psoriasis…

Filed under:Drug Updates Tagged with:genital psoriasisixekizumabPsoriasissexual health

Apremilast Promising for Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  July 6, 2020

Apremilast has been shown to improve the signs and symptoms of mild to moderate plaque psoriasis in adults, according to new research…

Filed under:AnalgesicsDrug Updates Tagged with:apremilastplaque psoriasisskin

Risankizumab Demonstrates Superiority to Secukinumab for Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  February 5, 2020

In a phase 3, comparator study in adults with plaque psoriasis, patients taking
risankizumab achieved greater skin clearance than those taking secukinumab…

Filed under:Drug Updates Tagged with:plaque psoriasisrisankizumabsecukinumab

Tildrakizumab Promising for Psoriasis in Patients with PsA

Michele B. Kaufman, PharmD, BCGP  |  December 2, 2019

New research shows tildrakizumab may significantly improve psoriasis in patients with active psoriatic arthritis…

Filed under:ConditionsDrug UpdatesPsoriatic Arthritis Tagged with:2019 ACR/ARP Annual MeetingPsoriasisPsoriatic Arthritistildrakizumab

  • 1
  • 2
  • 3
  • …
  • 55
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences